February 28, 2015 1:27 PM ET


Company Overview of Immunocore Limited

Company Overview

Immunocore Limited, a bio-technology company, discovers and develops bio-therapeutics for the treatment of cancer, viral diseases, and autoimmune diseases. It offers T cell receptors, a peptide antigen that presented on the surface of cells by human leukocyte antigen molecules; and IMCgp100, a novel bi-specific immunotherapeutic for the treatment of malignant melanoma. Immunocore Limited was formerly known as Avidex Limited and changed its name to Immunocore Limited in October 2008. The company was founded in 1999 and is based in Abingdon, United Kingdom.

91 Park Drive

Milton Park

Abingdon,  OX14 4RY

United Kingdom

Founded in 1999


44 12 3543 8600


44 12 3543 8601

Key Executives for Immunocore Limited

Executive Chairman and Interim Chief Executive Officer
Age: 66
Founder and Chief Scientific Officer
Chief Business Officer and Director
Age: 55
Head of Business Development
Compensation as of Fiscal Year 2014.

Immunocore Limited Key Developments

Immunocore Limited Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 03:15 PM

Immunocore Limited Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 03:15 PM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Eli Lilly and Company and Immunocore Limited Enter Immunotherapy Agreement to Co-Discover and Co-Develop Novel Cancer Therapies

Eli Lilly and Company and Immunocore Limited announced they have entered into a co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapies. Using Immunocore's Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology, the companies will seek to use the power of the body's own immune system to attack cancer cells. ImmTACs have shown potential to direct a patient's T cells to specifically target the cancerous cells, avoiding damage to healthy cells. Under the terms of the agreement, Immunocore will receive an upfront fee of $15 million per program for the discovery of novel ImmTACs against jointly-selected cancer targets in order to generate preclinical candidate packages. If Lilly accepts a preclinical candidate package to develop and potentially commercialize, Immunocore will receive an opt-in fee of $10 million and will have an option to continue co-development with Lilly on a cost-sharing and profit-sharing basis. If Immunocore does not exercise its option, it will be entitled to potential future significant milestone and royalty payments.

Immunocore Limited Presents at Citi European Healthcare Conference, Jun-18-2014

Immunocore Limited Presents at Citi European Healthcare Conference, Jun-18-2014 . Venue: Stirling Square, 5-7 Carlton Gardens, London SW1Y 5AD, United Kingdom. Speakers: Eva-Lotta Allan, CBO.

Similar Private Companies By Industry

Company Name Region
Bio Products Laboratory Ltd Europe
AGI Biopharmaceuticals, Ltd. Europe
DestiNA Genomics Ltd Europe
Ingenza Ltd. Europe
Molecular Sensing Plc Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Immunocore Limited, please visit www.immunocore.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.